Phase II study on combined intravenous and intra-arterial chemotherapy with gemcitabine and mitomycin C in patients with advanced pancreatic cancer

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1492-1496

  Heinrich, Stefan ^a,b   Kraft, Daniela ^a   Staib Sebler, Elsbeth ^a   Schwarz, Wolfram ^a   Gog, Christiane ^a   Vogl, Thomas ^a   Lorenz, Matthias ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Celiac artery infusion; Gemcitabine; Mitomycin C; Regional chemotherapy

Indexed keywords

CA 19-9 ANTIGEN; DEXAMETHASONE; GEMCITABINE; MITOMYCIN; ONDANSETRON; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANGIOGRAPHIC CATHETER; ARTERY THROMBOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELIAC ARTERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISTANT METASTASIS; DRUG DOSE REDUCTION; FEMALE; HUMAN; MALE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REGIONAL PERFUSION; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOMYCIN; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84885820836     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11805     Document Type: Article

References (27)

1. Black R: Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33:1075-1107.
2. Brennan M, Kinsella T, Casper E: Cancer of the pancreas. In: DeVita VT Jr HS, Rosenberg SA, ed. Cancer: principles&practice in oncology. Philadelphia: JB Lippincott Co, 1993:849-882.
3. Moore M: Activity of gemcitabine in patients with advanced pancreatic carcinoma. Cancer 1996; 78:633-638.
4. Crooke ST, Bradner WT: Mitomycin C: a review. Cancer Treat Rev 1976; 3:121-139.
5. Plunkett W, Huang P, Searcy CE, Gandhi V: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23:3-15. (Pubitemid 26362189)
6. Burris HA, 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413. (Pubitemid 27251144)
7. Carmichael J, Fink U, Russell RC, et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73:101-105. (Pubitemid 26026268)
8. Casper ES, Green MR, Kelsen DP, et al.: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12:29-34. (Pubitemid 24209062)
9. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 85:1261-1268. (Pubitemid 29125078)
10. Heinrich S, Schafer M, Bauerfeind P, Pestalozzi BC, Clavien PA: (Current diagnosis and treatment of pancreatic cancer). Praxis 2005; 94:1243-1254. (Pubitemid 41207516)
11. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
12. Lorenz M, Heinrich S, Staib-Sebler E, et al.: Regional chemotherapy in the treatment of advanced pancreatic cancer - is it relevant? Eur J Cancer 2000; 36:957-965. (Pubitemid 30316419)
13. Heinemann V, Schalhorn A, Schulz L, et al.: Pharmacokinetics of gemcitabine in patients with advanced pancreatic cancer. Onkologie 1997; 20:56.
14. Avital I: Regional chemotherapy for pancreatic cancer. J Surg Oncol 2011; 104:453.
15. Lorenz M, Heinrich S: Regional chemotherapy. Hematol Oncol Clin North Am 2002; 16:199-215. (Pubitemid 34578633)
16. Forster H, Emanuel E, Grady C: The 2000 revision of the Declaration of Helsinki: a step forward or more confusion? Lancet 2001;358:1449-1453. (Pubitemid 33055755)
17. Haskell C: Cancer treatment. In: Haskell C, ed. Cancer treatment. Philadelphia: WB Saunders Co, 1995:1164-1169.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47:207-214. (Pubitemid 11167383)
19. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
20. Kawarada Y, Isaji S: Stage classifications of pancreatic cancer: comparison of the Japanese and UICC classifications and proposal for a new staging system. Union Internationale Contre le Cancer. Pancreas 1998; 16:255-264. (Pubitemid 28158026)
21. Miyanishi K, Ishiwatari H, Hayashi T, et al.: A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization. Jpn J Clin Oncol 2008; 38:268-274. (Pubitemid 351583990)
22. Cantore M, Fiorentini G, Luppi G, et al.: Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother 2004; 16:589-594.
23. Ikeda O, Kusunoki S, Kudoh K, et al.: Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma. Cardiovasc Intervent Radiol 2006; 29:362-370.
24. Klapdor R, Seutter E, Lang-Polckow EM, Reichle H, Hinrichs A: Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers. Anticancer Res 1999; 19:2459-2469. (Pubitemid 29392393)
25. Heinemann V, Schermuly MM, Stieber P, et al.: CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 1999; 19:2433-2435. (Pubitemid 29392389)
26. Gattani AM, Mandeli J, Bruckner HW: Tumor markers in patients with pancreatic carcinoma. Cancer 1996; 78:57-62. (Pubitemid 26189905)
27. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF: Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6:462-468. (Pubitemid 18090693)